Pantozol Control

Țară: Uniunea Europeană

Limbă: engleză

Sursă: EMA (European Medicines Agency)

Cumpara asta acum

Prospect Prospect (PIL)
25-05-2023

Ingredient activ:

pantoprazole

Disponibil de la:

Takeda GmbH

Codul ATC:

A02BC02

INN (nume internaţional):

pantoprazole

Grupul Terapeutică:

Proton pump inhibitors

Zonă Terapeutică:

Gastroesophageal Reflux

Indicații terapeutice:

Short-term treatment of reflux symptoms (e.g. heartburn, acid regurgitation) in adults.

Rezumat produs:

Revision: 17

Statutul autorizaţiei:

Authorised

Data de autorizare:

2009-06-11

Prospect

                                22
B. PACKAGE LEAFLET
23
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
PANTOZOL CONTROL 20 MG GASTRO-RESISTANT TABLETS
pantoprazole
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
Always take this medicine exactly as described in this leaflet or as
your doctor or pharmacist have told
you.
-
Keep this leaflet. You may need to read it again.
-
Ask your pharmacist if you need more information or advice.
-
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
-
You must talk to a doctor if you do not feel better or if you feel
worse after 2 weeks.
-
You should not take PANTOZOL Control tablets for more than 4 weeks
without consulting a
doctor.
WHAT IS IN THIS LEAFLET
1.
What PANTOZOL Control is and what it is used for
2.
What you need to know before you take PANTOZOL Control
3.
How to take PANTOZOL Control
4.
Possible side effects
5.
How to store PANTOZOL Control
6.
Contents of the pack and other information
1.
WHAT PANTOZOL CONTROL IS AND WHAT IT IS USED FOR
PANTOZOL Control contains the active substance pantoprazole, which
blocks the ‘pump’ that
produces stomach acid. Hence it reduces the amount of acid in your
stomach.
PANTOZOL Control is used for the short-term treatment of reflux
symptoms (for example heartburn,
acid regurgitation) in adults.
Reflux is the backflow of acid from the stomach into the gullet
(“foodpipe”), which may become
inflamed and painful. This may cause you symptoms such as a painful
burning sensation in the chest
rising up to the throat (heartburn) and a sour taste in the mouth
(acid regurgitation).
You may experience relief from your acid reflux and heartburn symptoms
after just one day of
treatment with PANTOZOL Control, but this medicine is not meant to
bring immediate relief. It may
be necessary to take the tablets for 2-3 consecutive days to relieve
the symptoms.
_ _
You must talk to a doctor if you do not feel bet
                                
                                Citiți documentul complet
                                
                            

Caracteristicilor produsului

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
PANTOZOL Control 20 mg gastro-resistant tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each gastro-resistant tablet contains 20 mg pantoprazole (as sodium
sesquihydrate).
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Gastro-resistant tablet.
Yellow, oval, biconvex film-coated tablets imprinted with “P20” in
brown ink on one side.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
PANTOZOL Control is indicated for short-term treatment of reflux
symptoms (e.g. heartburn, acid
regurgitation) in adults.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
The recommended dose is 20 mg pantoprazole (one tablet) per day.
It might be necessary to take the tablets for 2-3 consecutive days to
achieve improvement of
symptoms. Once complete relief of symptoms has occurred, treatment
should be discontinued.
The treatment should not exceed 4 weeks without consulting a doctor.
If no symptom relief is obtained within 2 weeks of continuous
treatment, the patient should be
instructed to consult a doctor.
Special populations
No dose adjustment is necessary in elderly patients or in those with
impaired renal or liver function.
_ _
_Paediatric population _
_ _
PANTOZOL Control is not recommended for use in children and
adolescents below 18 years of age
due to insufficient data on safety and efficacy.
Method of administration
PANTOZOL Control 20 mg gastro-resistant tablets should not be chewed
or crushed, and should be
swallowed whole with liquid before a meal.
3
4.3
CONTRAINDICATIONS
Hypersensitivity to the active substance or to any of the excipients
listed in section 6.1.
Co-administration of pantoprazole is not recommended with HIV protease
inhibitors for which
absorption is dependent on acidic intragastric pH such as atazanavir,
nelfinavir; due to significant
reduction in their bioavailability (see section 4.5).
4.4
SPECIAL WARNINGS AND PRECAUTIONS FOR USE
Patients should be instructed to consult a doctor if:
•
Th
                                
                                Citiți documentul complet
                                
                            

Documente în alte limbi

Prospect Prospect bulgară 25-05-2023
Caracteristicilor produsului Caracteristicilor produsului bulgară 25-05-2023
Raport public de evaluare Raport public de evaluare bulgară 02-05-2013
Prospect Prospect spaniolă 25-05-2023
Caracteristicilor produsului Caracteristicilor produsului spaniolă 25-05-2023
Raport public de evaluare Raport public de evaluare spaniolă 02-05-2013
Prospect Prospect cehă 25-05-2023
Caracteristicilor produsului Caracteristicilor produsului cehă 25-05-2023
Raport public de evaluare Raport public de evaluare cehă 02-05-2013
Prospect Prospect daneză 25-05-2023
Caracteristicilor produsului Caracteristicilor produsului daneză 25-05-2023
Raport public de evaluare Raport public de evaluare daneză 02-05-2013
Prospect Prospect germană 25-05-2023
Caracteristicilor produsului Caracteristicilor produsului germană 25-05-2023
Raport public de evaluare Raport public de evaluare germană 02-05-2013
Prospect Prospect estoniană 25-05-2023
Caracteristicilor produsului Caracteristicilor produsului estoniană 25-05-2023
Raport public de evaluare Raport public de evaluare estoniană 02-05-2013
Prospect Prospect greacă 25-05-2023
Caracteristicilor produsului Caracteristicilor produsului greacă 25-05-2023
Raport public de evaluare Raport public de evaluare greacă 02-05-2013
Prospect Prospect franceză 25-05-2023
Caracteristicilor produsului Caracteristicilor produsului franceză 25-05-2023
Raport public de evaluare Raport public de evaluare franceză 02-05-2013
Prospect Prospect italiană 25-05-2023
Caracteristicilor produsului Caracteristicilor produsului italiană 25-05-2023
Raport public de evaluare Raport public de evaluare italiană 02-05-2013
Prospect Prospect letonă 25-05-2023
Caracteristicilor produsului Caracteristicilor produsului letonă 25-05-2023
Raport public de evaluare Raport public de evaluare letonă 02-05-2013
Prospect Prospect lituaniană 25-05-2023
Caracteristicilor produsului Caracteristicilor produsului lituaniană 25-05-2023
Raport public de evaluare Raport public de evaluare lituaniană 02-05-2013
Prospect Prospect maghiară 25-05-2023
Caracteristicilor produsului Caracteristicilor produsului maghiară 25-05-2023
Raport public de evaluare Raport public de evaluare maghiară 02-05-2013
Prospect Prospect malteză 25-05-2023
Caracteristicilor produsului Caracteristicilor produsului malteză 25-05-2023
Raport public de evaluare Raport public de evaluare malteză 02-05-2013
Prospect Prospect olandeză 25-05-2023
Caracteristicilor produsului Caracteristicilor produsului olandeză 25-05-2023
Raport public de evaluare Raport public de evaluare olandeză 02-05-2013
Prospect Prospect poloneză 25-05-2023
Caracteristicilor produsului Caracteristicilor produsului poloneză 25-05-2023
Raport public de evaluare Raport public de evaluare poloneză 02-05-2013
Prospect Prospect portugheză 25-05-2023
Caracteristicilor produsului Caracteristicilor produsului portugheză 25-05-2023
Raport public de evaluare Raport public de evaluare portugheză 02-05-2013
Prospect Prospect română 25-05-2023
Caracteristicilor produsului Caracteristicilor produsului română 25-05-2023
Raport public de evaluare Raport public de evaluare română 02-05-2013
Prospect Prospect slovacă 25-05-2023
Caracteristicilor produsului Caracteristicilor produsului slovacă 25-05-2023
Raport public de evaluare Raport public de evaluare slovacă 02-05-2013
Prospect Prospect slovenă 25-05-2023
Caracteristicilor produsului Caracteristicilor produsului slovenă 25-05-2023
Raport public de evaluare Raport public de evaluare slovenă 02-05-2013
Prospect Prospect finlandeză 25-05-2023
Caracteristicilor produsului Caracteristicilor produsului finlandeză 25-05-2023
Raport public de evaluare Raport public de evaluare finlandeză 02-05-2013
Prospect Prospect suedeză 25-05-2023
Caracteristicilor produsului Caracteristicilor produsului suedeză 25-05-2023
Raport public de evaluare Raport public de evaluare suedeză 02-05-2013
Prospect Prospect norvegiană 25-05-2023
Caracteristicilor produsului Caracteristicilor produsului norvegiană 25-05-2023
Prospect Prospect islandeză 25-05-2023
Caracteristicilor produsului Caracteristicilor produsului islandeză 25-05-2023
Prospect Prospect croată 25-05-2023
Caracteristicilor produsului Caracteristicilor produsului croată 25-05-2023

Căutați alerte legate de acest produs

Vizualizați istoricul documentelor